Hepatology

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on the role of advocacy and patient voice in HBV management.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on the most pressing unmet needs in HBV for 2024.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on updates in the therapeutic pipeline.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on the need to improve HBV screening and vaccination.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on how advancing understanding of HBV DNA integration is influencing care in 2024.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on advances in the pathophysiology of hepatitis b virus for 2024.

Microbiota differences between individuals with and without MAFLD were associated with dietary intake and clinical outcomes.

Zhang explains disparities in HCC care and the negative impact on long-term outcomes, also addressing potential considerations for vulnerable patient populations.

Results presented at DDW detail the association between ALT, Fibroscan CAP, Fibroscan VCTE, and histological response to resmetirom in patients enrolled in MAESTRO-NASH.

In this Q&A, Levy discusses the current treatment landscape for PBC and what clinical trial data suggest about seladelpar’s potential for these patients.

Interim results from the open-label, phase 3 study show seladelpar demonstrated clinically meaningful improvements in markers of cholestasis and liver injury.

HCV testing was accepted by more than 80% of patients undergoing mammography and resulted in prompt linkage to care.

Patients who missed their initial HCV treatment appointment had greater housing instability, transportation difficulty, and a history of medication non-adherence.

An analysis of FDA Adverse Event Reporting System data suggests baloxavir marboxil has lower hepatic toxicity than oseltamivir and may be a safer option for patients with liver diseases.

Results of the single-center study showed HCV treatment from PCPs decreased from 2015-2022 but must be improved to help reach elimination goals.

Results showed metabolic dysfunction was an independent predictor of liver-related events and hepatocellular carcinoma in patients with chronic HCV who achieved SVR.

Study results highlight the role of HCV and alcohol use in the growing global disease burden posed by cirrhosis, which is projected to increase over the next 20 years.

The CRL for the sBLA cites a lack of sufficient data to support the full evaluation of the effectiveness and safety of a 4-dose regimen in this patient population.

At APA 2024, Weinrieb discussed the positive patient outcomes of using a psychiatry-hepatology approach for the treatment of alcohol-associated liver disease.

A novel score based on a combination of cytokeratins and routine laboratory tests provided a more accurate diagnosis of HCC versus serum α-fetoprotein alone.

Glecaprevir/pibrentasvir is an effective treatment for HCV with high rates of SVR, even in patients with cirrhosis undergoing a shorter treatment regimen.

A Veterans Affairs study finds low alpha-1 antitrypsin phenotyping rates, indicating the need for improved healthcare provider education on AATD.

This clinical quiz will test your knowledge of the 2023 American Association for the Study of Liver Diseases/Infectious Diseases Society of America Hepatitis C guideline.

Results suggest chronic hepatitis B virus is globally underassessed and undertreated, especially among women and Asian minorities in the West.

Sofosbuvir/velpatasvir/voxilaprevir rescue therapy was safe and effective, and SVR did not significantly differ based on genotype, cirrhosis, or first-line therapy.

Findings suggest unstable housing may inhibit direct-acting antiviral treatment initiation in PWID with unstable housing compared to those with stable housing.

Maralixibat oral solution improved pruritus and native liver survival in PFIC patients in the MARCH-PFIC trial.

Vitamin D concentration was significant in chronic hepatitis B virus but not hepatitis C virus infection, suggesting its potential impact on immune response.

Results showed 46.45 and 72.74% increases in the global incidences of acute infection and HCV-related cirrhosis, respectively, in reproductive-age women.

Findings suggest metformin and statins have a potective effect against HCC in patients with HCV who fail antiviral therapy.